OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference
07 févr. 2022 08h30 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Feb. 07, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences
03 janv. 2022 08h30 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea., Jan. 03, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board with Appointment of Nucleic Acid Therapeutics and Immunology Specialist Dr. Gunther Hartmann
30 nov. 2021 08h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Nov. 30, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther...
OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference
21 oct. 2021 12h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A
20 oct. 2021 08h30 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 20, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected...
Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China
12 oct. 2021 07h00 HE
|
OliX Pharmaceuticals; Hansoh Pharmaceutical Group Co, Ltd
Companies to focus on cardiovascular, metabolic, and other indicationsOliX will receive initial upfront payment of $6.5 million with up to $450 million plus royalties SHANGHAI, China and SUWON,...
OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference
24 sept. 2021 08h30 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present new...
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Investigational Hair Loss Therapeutic, OLX104C
12 août 2021 09h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received a...
OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate
04 août 2021 09h00 HE
|
OliX Pharmaceuticals
- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit
14 juin 2021 10h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...